Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cellsMegen C Wittling, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Anna C Cole, Gregory B Lesinski, Chrystal M Paulos
30 June 2024
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretionYuanyuan Chen, Dijun Ouyang, Yan Wang, Qiuzhong Pan, Jingjing Zhao, Hao Chen, Xinyi Yang, Yan Tang, Qijing Wang, Yongqiang Li, Jia He, Jin-Qi You, Yingzi Li, Chi Xu, Yan RenSee the full list of authors
17 June 2024
An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cellsMatthew Ryan Sullivan, Michael Finocchiaro, Yichao Yang, Judene Thomas, Alaa Ali, Isabel Kaplan, Yasmin Abdulhamid, Eden Bobilev, Michal Sheffer, Rizwan Romee, Tania Konry
31 May 2024
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypesNoam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu, Sivasish Sindiri, Jared J Gartner, Maria Parkhurst, Sri Krishna, Frank J Lowery, Nikolaos Zacharakis, Lior Levy, Todd D Prickett, Tiffany Benzine, Satyajit RaySee the full list of authors
30 May 2024
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in ChinaWenyan Yu, Liang Huang, Heng Mei, Yuhua Li, Ting Niu, Dehui Zou, Yao Liu, Huilai Zhang, Peng Liu, Jianqiu Wu, Zhi Wang, Hui Li, Qingqing Cai, Jian-qing Mi
27 May 2024
Developing a membrane-proximal CD33-targeting CAR T cellRuby Freeman, Sanam Shahid, Abdul G Khan, Serena C Mathew, Sydney Souness, Erin R Burns, Jasmine S Um, Kento Tanaka, Winson Cai, Sarah Yoo, Andrew Dunbar, Young Park, Devin McAvoy, Kinga K Hosszu, Ross L LevineSee the full list of authors
20 May 2024
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancersTessa Gargett, Nga T H Truong, Bryan Gardam, Wenbo Yu, Lisa M Ebert, Amy Johnson, Erica C F Yeo, Nicole L Wittwer, Gonzalo Tapia Rico, Jesikah Logan, Purany Sivaloganathan, Maria Collis, Andrew Ruszkiewicz, Michael P Brown
15 May 2024
Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settingsNicolas Poirier, Valérie Paquin, Séverine Leclerc, Véronique Lisi, Carolina Marmolejo, Hicham Affia, Paulo Cordeiro, Yves Théorêt, Elie Haddad, Gregor Andelfinger, Vincent Philippe Lavallée, Michel Duval, Sabine Herblot
15 May 2024
Stealth transgenes enable CAR-T cells to evade host immune responsesKorneel Grauwet, Trisha Berger, Michael C Kann, Harrison Silva, Rebecca Larson, Mark B Leick, Stefanie R Bailey, Amanda A Bouffard, David Millar, Kathleen Gallagher, Cameron J Turtle, Matthew J Frigault, Marcela V Maus
9 May 2024
ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBMXinmiao Long, Zuping Zhang, Yuzhe Li, Kun Deng, Wei Gao, Meng Huang, Xiangyu Wang, Xiang Lin, Xiaoling She, Yiming Zhao, Minfu Zhang, Cheng Huang, Shiyi Wang, Yinfei Du, Peng DuSee the full list of authors
30 April 2024